Biome delivers record Q1 revenue of $5.94m, seventh consecutive quarter of positive EBITDA
Key points
- Record quarterly sales revenue of $5.94m, up 40% vs PCP and 19% QoQ
- Seventh consecutive quarter of positive EBITDA at $462k
- Cash receipts of $7.14m, up 84% vs PCP
Full summary
Microbiome health company Biome Australia Limited (ASX: BIO) has delivered record quarterly sales revenue of $5.94m, representing growth of 40% on the prior corresponding period and 19% quarter-on-quarter. The company has now achieved rolling 12-month sales revenue surpassing $20m. The first quarter of FY26 marks Biome's seventh consecutive quarter of positive EBITDA, reaching $462k. Cash receipts for the quarter were $7.14m (up 84% vs PCP), generating net operating cash inflow of $918k. The difference between operating cash inflow and the cash balance increase of $189k reflects the net effect of $711k in working capital facilities repayment, a $29K payment for lease liabilities, a $61k receipt for the extinguishment of a loan under the Company's Employee Loan Funded Share Plan and $50k in investing activities, demonstrating Biome's commitment to strengthening its balance sheet while maintaining operational momentum. Cash at 30 September 2025 was $2.94m. Biome maintained its gross margin above 61% for Q1 FY26.
Guidance
The company has achieved an annualised run-rate of ~$24m based on Q1 FY26 performance.
Outlook
Biome's focus is on scaling its international operations and driving continued domestic growth, while maintaining positive EBITDA.
Summary generated by a large language model. Please interpret with care.